D: Filing D
Apr 26 04:08
NeuroSense Therapeutics | 424B5: Prospectus
Apr 13 04:35
NeuroSense Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Apr 13 04:33
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Apr 10 21:02
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Apr 9 20:35
NeuroSense Therapeutics | EFFECT: Others
Apr 9 18:04
NeuroSense Therapeutics | EFFECT: Others
Apr 9 18:04
NeuroSense Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Apr 5 21:33
NeuroSense Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Apr 5 05:12
NeuroSense Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Apr 5 04:42
NeuroSense Therapeutics | 20-F: Registration statement / Annual report / Transition report
Apr 5 04:37
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Feb 22 21:31
NeuroSense Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ariel Gordon.(6.9%)
Feb 14 02:25
NeuroSense Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Alon Ben-Noon(19.98%)
Feb 13 23:19
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Feb 7 22:40
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Jan 9 13:00
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Jan 9 13:00
NeuroSense Therapeutics | 424B3: Prospectus
Dec 27, 2023 13:00
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Dec 27, 2023 13:00
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Dec 21, 2023 21:45
No Data
No Data